Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 4, 1996, Pages 382-390

  Maurer, Anne Marie ^b   Han, Zhong Chao ^b   Dhermy, Didier ^b   Briere, Jean ^a  

^a BEAUJON HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; GLYCOSIDE; GROWTH INHIBITOR; HEPARAN SULFATE; POLYSACCHARIDE LYASE; PROTAMINE; THROMBOCYTE FACTOR 4;

ARTICLE; CELL CULTURE; CELL DIVISION; CELL MEMBRANE; CULTURE MEDIUM; DRUG EFFECT; ERYTHROLEUKEMIA; HUMAN; METABOLISM; PATHOLOGY;

CELL DIVISION; CELL MEMBRANE; CULTURE MEDIA, SERUM-FREE; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCANS; GLYCOSIDES; GROWTH INHIBITORS; HEPARITIN SULFATE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; PLATELET FACTOR 4; POLYSACCHARIDE-LYASES; PROTAMINES; TUMOR CELLS, CULTURED;

EID: 0030116792     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90186-9     Document Type: Article

References (37)

1. Ryo R, Proffitt RT, Poger ME, O'Bear R, Deuel TF. Platelet factor 4 antigene in megakaryocytes. Thromb Res 1980;17:645-52.
2. Hegyi E, Heilburn LK, Nakeff A. Immunogold probing of platelet factor 4 in different ploidy classes of rat megakaryocytes sorted by flow cytometry. Exp Hematol 1990;18:789-93.
3. McLaren KM, Holloway L, Pepper DS. Human platelet factor 4 and tissue mast cells. Thromb Res 1980;19:293-7.
4. Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982;27:65-76.
5. Ryo R, Nakeff A, Huang SS, Ginsberg M, Deuel TF. New synthesis of a platelet-specific protein: platelet factor 4 synthesis in megakaryocyte-enriched rabbit bone marrow culture system. J Cell Biol 1983;96:515-20.
6. Moore S, Pepper DS, Cash JD. Platelet antiheparin activity: the isolation and the characterization of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound antiheparin activity. Biochim Biophys Acta 1975;379:370-84.
7. Barber AJ, Käser-Glanzmann B, Jakabova M, Lüscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 1972;286:312-29.
8. Huang SS, Huang JS, Deuel TF. Proteoglycan carrier of human platelet factor 4: isolation and characterization. J Biol Chem 1982;257:11546-50.
9. Handin RI, Cohen HJ. Purification and binding of human platelet factor four. J Biol Chem 1976;251:4273-82.
10. Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor 4 and glycosaminoglycans. Arch Biochim Biophys 1985;240:446-55.
11. Hermodson M, Schmer G, Kurachi K. Isolation, crystallization, and primary amino acid sequence of human platelet factor 4. J Biol Chem 1977;252:6276-9.
12. Sharp RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990;82:848-53.
13. Maione TE, Gray GS, Petro J. Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science 1990;247:77-9.
14. Gewirtz AM, Calabretta B, Rucinski B, Niewiarowski S, Xu YW. Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest 1989;83:1477-86.
15. Han ZC, Sensébé L, Abgrall JF, Brière J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 1990;5: 1234-9.
16. Han ZC, Bellucci S, Tenza D, Caen JP. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and β- thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythemia and immune thrombocytopenic purpura. Br J Haematol 1989;74:395-401.
17. Han ZC, Bellucci S, Walz D, Baggiolini M, Caen JP. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide (CTAP-III). Int J Cell Cloning 1990;8:253-9.
18. Han ZC, Bellucci S, Bodevin E, Wan HY, Shen ZX, Caen JP. In vivo inhibition of megakaryocyte and platelet production by platelet factor 4 in mice. Comptes Rendus de l'Académie des Sciences (Paris) 1991;313:553-8.
19. Deuel TF, Senior RM, Chang D, Griffin GL, Heinrickson RL. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981;78:4854-7.
20. Senior RM, Griffin GL, Huang JS, Walz DA, Deuel DF, Heinrickson RL. Chemotactic activity of platelet alpha granule proteins for fibroblasts. J Cell Physiol 1981;96:382-85.
21. Han ZC, Maurer AM, Bellucci S, et al. Inhibitory effect of platelet factor 4 (PF4) on the growth of human erythroleukemia cells: proposed mechanism of action of PF4. J LAB CLIN MED 1992;120:645-60.
22. Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ. Antiheparin proteins secreted by human platelets. Purification, characterization and radioimmunoassay. Blood 1979;53:47-62.
23. Rapraeger A, Yeaman C. A quantitative solid-phase assay for identifying radiolabeled glycosaminoglycans in crude cell extracts. Anal Bioch 1989;179:361-5.
24. Mostcatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 1987;131:123-30.
25. Luikart SD, Sackrison JL, Thomas V. Altered glycosaminoglycan production by HL60 cells treated with 4-methylumbelliferyl-β-D-xyloside. Blood 1985;66:866-72.
26. Johnston LS, Keller JM. The effect of β-xylosides on heparan sulfate synthesis by SV40-transformed Swiss Mouse 3T3 cells. J Biol Chem 1979;254:2575-8.
27. Parkinson JF, Garcia JGN, Bang NU. Decreased thrombin affinity of cell-surface thrombomodulin following treatment of cultured endothelial cells with β-D-xyloside. Biochem Biophys Res Commun 1991;69:177-83.
28. Rybak ME, Gimbrone MA, Davies PF, Handin RI. Interaction of platelet factor four with cultured vascular endothelial cells. Blood 1989;73:1534-9.
29. Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980;19:129-37.
30. Casu B, Petitou M, Provasoli M, Sinaÿ P. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 1990;13:221-5.
31. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989;58: 575-606.
32. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990;172:595-600.
33. Sato Y, Waki M, Ohno M, Kuwano M, Sakata T. Carboxylterminal heparin-binding fragments of platelet factor 4 retain the blocking effect on the receptor binding of basic fibroblast growth factor. Jpn J Cancer Res 1993;84:485-8.
34. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-8.
35. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991;252:1705-7.
36. Bikfalvi A, Han ZC, Fuhrmann G. Interaction of fibroblast growth factor (FGF) with megakaryocytopoiesis and demonstration of FGF receptor expression in megakaryocytes and megacaryocytic-like cells. Blood 1992;80:1905-13.
37. Kjellen L, Lindhal U. Proteoglycans: structure and interactions. Annu Rev Biochem 1991;60:443-75.